

Title: Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13

Journal: The Patient

Authors: Cheryl D. Coon, Michael Schlichting, Xinke Zhang

Corresponding Author: Cheryl D. Coon, Outcometrix, ccoon@outcometrix.com

Online Resource 6: Distribution-based estimates for EORTC domain scores (N=681)

EORTC Domain Score	Test-Retest Reliability [a]	1/2 Standard Deviation [b]	Standard Error of Measurement
EORTC QLQ-C30			
Role Functioning	0.66	12.48	14.59
Emotional Functioning	0.75	10.32	10.28
Cognitive Functioning	0.73	9.59	10.04
Social Functioning	0.62	11.05	13.61
Fatigue	0.75	11.56	11.61
Nausea and Vomiting	0.74	7.86	8.06
Pain	0.79	12.92	11.75
Dyspnea	0.67	13.59	15.59
Insomnia	0.68	14.08	15.95
Appetite Loss	0.79	13.84	12.54
Constipation	0.73	12.40	12.98
Diarrhea	0.53	5.67	7.77
EORTC QLQ-LC13			
Hemoptysis	0.72	7.06	7.45
Sore Mouth	0.54	7.96	10.77
Dysphagia	0.76	7.99	7.76
Peripheral Neuropathy	0.79	13.04	11.81
Alopecia	0.48	11.43	16.42
Pain in Arm or Shoulder	0.70	12.70	13.85
Pain in Other Parts	0.57	13.10	17.13
Take Any Medication for Pain	0.71	8.34	8.95

[a] Test-retest reliability is the intraclass correlation coefficient using a two-way mixed effects regression model based on absolute agreement with screening data as the “test” administration and Week 1 data as the “retest” administration, using only participants who report the same value on the Global Health Status item at both administrations.

[b] Based on Baseline scores.